SEARCH

SEARCH BY CITATION

References

  • Adage, T., Trillat, A.C., Quattropani, A., Perrin, D., Cavarec, L., Shaw, J., Guerassimenko, O., Giachetti, C., Gréco, B., Chumakov, I., Halazy, S., Roach, A. & Zaratin, P. (2008) In vitro and in vivo pharmacological profile of AS057278, a selective d-amino acid oxidase inhibitor with potential anti-psychotic properties. Eur Neuropsychopharmacol 18, 200214.
  • Almond, S.L., Fradley, R.L., Armstrong, E.J., Heavens, R.B., Rutter, A.R., Newman, R.J., Chiu, C.S., Konno, R., Hutson, P.H. & Brandon, N.J. (2006) Behavioral and biochemical characterization of a mutant mouse strain lacking D-amino acid oxidase activity and its implications for schizophrenia. Mol Cell Neurosci 32, 324334.
  • Barnett, J.H., Croudace, T.J., Jaycock, S., Blackwell, C., Hynes, F., Sahakian, B.J., Joyce, E.M. & Jones, P.B. (2007) Improvement and decline of cognitive function in schizophrenia over one year: a longitudinal investigation using latent growth modelling. BMC Psychiatry 7, 16.
  • Bendikov, I., Nadri, C., Amar, S., Panizzutti, R., De Miranda, J., Wolosker, H. & Agam, G. (2007) A CSF and postmortem brain study of D-serine metabolic parameters in schizophrenia. Schizophr Res 90, 4151.
  • Berman, I., Viegner, B., Merson, A., Allan, E., Pappas, D. & Green, A.I. (1997) Differential relationships between positive and negative symptoms and neuropsychological deficits in schizophrenia. Schizophr Res 25, 110.
  • Chumakov, I., Blumenfeld, M., Guerassimenko, O. et al. (2002) Genetic and physiological data implicating the new human gene G72 and the gene for D-amino acid oxidase in schizophrenia. Proc Natl Acad Sci U S A 99, 1367513680.
  • Cohen, E., Sereni, N., Kaplan, O., Weizman, A., Kikinzon, L., Weiner, I. & Lubow, R.E. (2004) The relation between latent inhibition and symptom-types in young schizophrenics. Behav Brain Res 2, 113122.
  • Corvin, A., McGhee, K.A., Murphy, K., Donohoe, G., Nangle, J.M., Schwaiger, S., Kenny, N., Clarke, S., Meagher, D., Quinn, J., Scully, P., Baldwin, P., Browne, D., Walsh, C., Waddington, J.L., Morris, D.W. & Gill, M. (2007) Evidence for association and epistasis at the DAOA/G30 and D-amino acid oxidase loci in an Irish schizophrenia sample. Am J Med Genet B Neuropsychiatr Genet 144B, 949953.
  • Coyle, J.T. (2006) Glutamate and schizophrenia: beyond the dopamine hypothesis. Cell Mol Neurobiol 26, 365384.
  • Duffy, S., Labrie, V. & Roder, J.C. (2008) D-serine augments NMDA-NR2B receptor-dependent hippocampal long-term depression and spatial reversal learning. Neuropsychopharmacology 33, 10041018.
  • Ellenbroek, B.A. & Cools, A.R. (2000) Animal models for the negative symptoms of schizophrenia. Behav Pharmacol 11, 223233.
  • Ferraris, D., Duvall, B., Ko, Y.S., Thomas, A.G., Rojas, C., Majer, P., Hashimoto, K. & Tsukamoto, T. (2008) Synthesis and biological evaluation of D-amino acid oxidase inhibitors. J Med Chem 51, 33573359.
  • Foltyn, V.N., Bendikov, I., De Miranda, J., Panizzutti, R., Dumin, E., Shleper, M., Li, P., Toney, M.D., Kartvelishvily, E. & Wolosker, H. (2005) Serine racemase modulates intracellular D-serine levels through an alpha, beta-elimination activity. J Biol Chem 280, 17541763.
  • Fradley, R.L., O’Meara, G.F., Newman, R.J., Andrieux, A., Job, D. & Reynolds, D.S. (2005) STOP knockout and NMDA NR1 hypomorphic mice exhibit deficits in sensorimotor gating. Behav Brain Res 163, 257264.
  • Fuchs, S.A., Berger, R., Klomp, L.W. & De Koning, T.J. (2005) D-amino acids in the central nervous system in health and disease. Mol Genet Metab 85, 168180.
  • Gaisler-Salomon, I., Diamant, L., Rubin, C. & Weiner, I. (2008)Abnormally persistent latent inhibition induced by MK801 is reversed by risperidone and by positive modulators of NMDA receptor function: differential efficacy depending on the stage of the task at which they are administered. Psychopharmacol 196, 255267.
  • Gaisler-Salomon, I. & Weiner, I. (2003) Systemic administration of MK-801 produces an abnormally persistent latent inhibition which is reversed by clozapine but not haloperidol. Psychopharmacology 166, 333342.
  • Geyer, M.A., Krebs-Thomson, K., Braff, D.L. & Swerdlow, N.R. (2001)Pharmacological studies of prepulse inhibition models sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology 156,117154.
  • Grant, S.L., Shulman, Y., Tibbo, P., Hampson, D.R. & Baker, G.B. (2006) Determination of D-serine and related neuroactive amino acids in human plasma by high-performance liquid chromatography with fluorimetric detection. J Chromatogr B Analyt Technol Biomed Life Sci 844, 278282.
  • Hashimoto, K., Fujita, Y., Horio, M., Kunitachi S., Iyo, M., Ferraris, D. & Tsukamoto, T. (2009) Co-administration of a D-amino acid oxidase inhibitor potentiates the efficacy of D-serine in attenuating prepulse inhibition deficits after administration of dizocilpine. Biol Psychiatry 65, 11031106.
  • Hashimoto, K., Fukushima, T., Shimizu, E., Komatsu, N., Watanabe, H., Shinoda, N., Nakazato, M., Kumakiri, C., Okada, S., Hasegawa, H., Imai, K. & Iyo, M. (2003) Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia. Arch Gen Psychiatry 60, 572576.
  • Hashimoto, A., Nishikawa, T., Konno, R., Niwa, A., Yasumura, Y., Oka, T. & Takahashi, K. (1993) Free D-serine, D-aspartate and D-alanine in central nervous system and serum in mutant mice lacking D-amino acid oxidase. Neurosci Lett 152, 3336.
  • Heresco-Levy, U., Javitt, D.C., Ebstein, R., Vass, A., Lichtenberg, P., Bar, G., Catinari, S. & Ermilov, M. (2005) D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia. Biol Psychiatry 57, 577585.
  • Javitt, D.C. & Zukin, S.R. (1991) Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148, 13011308.
  • Kapoor, R., Lim, K.S., Cheng, A., Garrick, T. & Kapoor, V. (2006)Preliminary evidence for a link between schizophrenia and NMDA-glycine site receptor ligand metabolic enzymes, d-amino acid oxidase (DAAO) and kynurenine aminotransferase-1 (KAT-1). Brain Res 1106, 205210.
  • Kew, J.N., Koester, A., Moreau, J.L., Jenck, F., Ouagazzal, A.M., Mutel, V., Richards, J.G., Trube, G., Fischer, G., Montkowski, A., Hundt, W., Reinscheid, R.K., Pauly-Evers, M., Kemp, J.A. & Bluethmann, H. (2000) Functional consequences of reduction in NMDA receptor glycine affinity in mice carrying targeted point mutations in the glycine binding site. J Clin Neurosci 20, 40374049.
  • Konno, R. & Yasumura, Y. (1983) Mouse mutant deficient in D-amino acid oxidase activity. Genetics 103, 277285.
  • Korostishevsky, M., Kaganovich, M., Cholostoy, A., Ashkenazi, M., Ratner, Y., Dahary, D., Bernstein, J., Bening-Abu-Shach, U., Ben-Asher, E., Lancet, D., Ritsner, M. & Navon, R. (2004) Is the G72/G30 locus associated with schizophrenia? single nucleotide polymorphisms, haplotypes, and gene expression analysis. Biol Psychiatry 56, 169176.
  • Krystal, J.H., Karper, L.P., Seibyl, J.P., Freeman G.K., Delaney, R., Bremner, J.D., Heninger, G.R., Bowers, M.B. Jr & Charney, D.S. (1994)Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51, 199214.
  • Labrie, V., Clapcote, S.J. & Roder, J.C. (2008a) Mutant mice with reduced NMDA-NR1 glycine affinity or lack of D-amino acid oxidase function exhibit altered anxiety-like behaviors. Pharmacol Biochem Behav 91, 610620.
  • Labrie, V., Duffy, S., Wei, W., Barger, S., Baker, G.B. & Roder, J.C. (2008b) Genetic inactivation of D-amino acid oxidase enhances extinction and reversal learning in mice. Learn Mem 16, 2837.
  • Labrie, V., Fukumura, R., Rastogi, A., Fick, L.J., Wang, W., Boutros, P.C., Kennedy, J.L., Semeralul, M.O., Lee, F.H., Baker, G.B., Belsham, D.D., Barger, S.W., Gondo, Y., Wong, A.H. & Roder J.C. (2009) Serine racemase is associated with schizophrenia susceptibility in humans and in a mouse model. Hum Mol Genet 18, 32273243.
  • Labrie, V., Lipina, T. & Roder, J.C. (2008c) Mice with reduced NMDA receptor glycine affinity model some of the negative and cognitive symptoms of schizophrenia. Psychopharmacology 200, 217230.
  • Lewis, D.A. & Gonzalez-Burgos, G. (2006) Pathophysiologically based treatment interventions in schizophrenia. Nature Med 12, 10161022.
  • Lipina, T., Labrie, V., Weiner, I. & Roder, J. (2005) Modulators of the glycine site on NMDA receptors, D-serine and ALX-5407, display similar beneficial effects to clozapine in mouse models of schizophrenia. Psychopharmacology 179, 5467.
  • Lipina, T., Weiss, K. & Roder, J. (2007) The ampakine CX546 restores the prepulse inhibition and latent inhibition deficits in mGluR5-deficient mice. Neuropsychopharmacology 32, 745756.
  • Liu, X., He, G., Wang, X. et al. (2004) Association of DAAO with schizophrenia in the Chinese population. Neurosci Lett 369, 228233.
  • Madeira, C., Freitas, M.E., Vargas-Lopes, C., Wolosker, H. & Panizzutti, R. (2008) Increased brain D-amino acid oxidase (DAAO) activity in schizophrenia. Schizophr Res 101, 7683.
  • Maekawa, M., Okamura, T., Kasai, N., Hori, Y., Summer, K.H. & Konno, R. (2005a) D-amino-acid oxidase is involved in D-serine-induced nephrotoxicity. Chem Res Toxicol 18, 16781682.
  • Maekawa, M., Watanabe, M., Yamaguchi, S., Konno, R. & Hori, Y. (2005b) Spatial learning and long-term potentiation of mutant mice lacking D-amino-acid oxidase. Neurosci Res 53, 3438.
  • Mandillo, S., Rinaldi, A., Oliverio, A. & Mele, A. (2003) Repeated administration of phencyclidine, amphetamine and MK-801 selectively impairs spatial learning in mice: a possible model of psychotomimetic drug-induced cognitive deficits. Behav Pharmacol 14, 533544.
  • Martineau, M., Baux, G. & Mothet, J.P. (2006) D-serine signalling in the brain: friend and foe. Trends Neurosci 29, 481491.
  • Miyakawa, T., Yared, E., Pak, J.H., Huang, F.L., Huang, K.P. & Crawley, J.N. (2001) Neurogranin null mutant mice display performance deficits on spatial learning tasks with anxiety related components. Hippocampus 11, 763775.
  • Moreno, S., Nardacci, R., Cimini, A. & Cerù, M.P. (1999) Immunocytochemical localization of D-amino acid oxidase in rat brain. J Neurocytol 28, 169185.
  • Morita, Y., Ujike, H., Tanaka, Y., Otani, K., Kishimoto, M., Morio, A., Kotaka, T., Okahisa, Y., Matsushita, M., Morikawa, A., Hamase, K., Zaitsu, K. & Kuroda, S. (2006) A genetic variant of the serine racemase gene is associated with schizophrenia. Biol Psychiatry 61, 12001203.
  • Morris, R.G., Anderson, E., Lynch, G.S. & Baudry, M. (1986) Selective impairment of learning and blockade of long-term potentiation by an N-methyl-D-aspartate receptor antagonist, AP5. Nature 319, 774776.
  • Moser, P.C., Hitchcock, J.M., Lister, S. & Moran, P.M. (2000) The pharmacology of latent inhibition as an animal model of schizophrenia. Brain Res Rev 33, 275307.
  • Mothet, J.P., Parent, A.T., Wolosker, H., Brady, R.O. Jr, Linden, D.J., Ferris, C.D., Rogawski, M.A. & Snyder, S.H. (2000) D-serine is an endogenous ligand for the glycine site of the N-methyl-D-aspartate receptor. Proc Natl Acad Sci U S A 97, 49264931.
  • Moy, S.S., Nadler, J.J., Perez, A., Barbaro, R.P., Johns, J.M., Magnuson, T.R., Piven, J. & Crawley J.N. (2004) Sociability and preference for social novelty in five inbred strains: an approach to assess autistic-like behavior in mice. Genes Brain Behav 3, 287302.
  • Moy, S.S., Perez, A., Koller, B.H. & Duncan, G.E. (2006) Amphetamine-induced disruption of prepulse inhibition in mice with reduced NMDA receptor function. Brain Res 1089, 186194.
  • O’Donnell, B.F., Swearer, J.M., Smith, L.T., Nestor, P.G., Shenton, M.E. & McCarley, R.W. (1996) Selective deficits in visual perception and recognition in schizophrenia. Am J Psychiatry 153, 687692.
  • Panatier, A., Theodosis, D.T., Mothet, J.P., Touquet, B., Pollegioni, L., Poulain, D.A. & Oliet, S.H. (2006) Glia-derived D-serine controls NMDA receptor activity and synaptic memory. Cell 125, 775784.
  • Rascle, C., Mazas, O., Vaiva, G., Tournant, M., Raybois, O., Goudemand, M. & Thomas, P. (2001) Clinical features of latent inhibition in schizophrenia. Schizophr Res 51, 149161.
  • Ross, C.A., Margolis, R.L., Reading, S.A., Pletnikov, M. & Coyle, J.T. (2006) Neurobiology of schizophrenia. Neuron 52, 139153.
  • Roullet, P., Mele, A. & Ammassari-Teule, M. (1996) Involvement of glutamatergic and dopaminergic systems in the reactivity of mice to spatial and non-spatial change. Psychopharmacology. 126, 5561.
  • Rung, J.P., Carlsson, A., Markinhuhta, K.R. & Carlsson, M.L. (2005)The dopaminergic stabilizers (-)-OSU6162 and ACR16 reverse (+)-MK-801-induced social withdrawal in rats. Prog Neuropsychopharmacol Biol Psychiatry 29, 833839.
  • Sankoorikal, G.M., Kaercher, K.A., Boon, C.J., Lee, J.K. & Brodkin, E.S. (2006) A mouse model system for genetic analysis of sociability: C57BL/6J versus BALB/cJ inbred mouse strains. Biol Psychiatry 59, 415423.
  • Sasaki, M., Konno, R., Nishio, M., Niwa, A., Yasumura, Y. & Enami, J. (1992) A single-base-pair substitution abolishes D-amino-acid oxidase activity in the mouse. Biochim Biophys Acta 1139, 315318.
  • Schell, M.J., Molliver, M.E. & Snyder, S.H. (1995)D-serine, an endogenous synaptic modulator: localization to astrocytes and glutamate-stimulated release. Proc Natl Acad Sci U S A 92, 39483952.
  • Schmitt, M.L., Coelho, W., Lopes-de-Souza, A.S., Guimarães, F.S. & Carobrez, A.P. (1995) Anxiogenic-like effect of glycine and D-serine microinjected into dorsal periaqueductal gray matter of rats. Neurosci Lett 189, 9396.
  • Schumacher, J., Jamra, R.A., Freudenberg, J., Becker, T., Ohlraun, S., Otte, A.C., Tullius, M., Kovalenko, S., Bogaert, A.V., Maier, W., Rietschel, M., Propping, P., Nöthen, M.M. & Cichon, S. (2004) Examination of G72 and D-amino acid oxidase as genetic risk factor for schizophrenia and bipolar affective disorder. Mol Psychiatry 9, 203207.
  • Shi, J., Badner, J.A., Gershon, E.S. & Liu, C. (2008) Allelic association of G72/G30 with schizophrenia and bipolar disorder: a comprehensive meta-analysis. Schizophr Res 98, 8997.
  • Shinkai, T., De Luca, V., Hwang, R., Müller, D.J., Lanktree, M., Zai, G., Shaikh, S., Wong, G., Sicard, T., Potapova, N., Trakalo, J., King, N., Matsumoto, C., Hori, H., Wong, A.H., Ohmori, O., Macciardi, F., Nakamura, J. & Kennedy J.L. (2007) Association analyses of the DAOA/G30 and D-amino-acid oxidase genes in schizophrenia: further evidence for a role in schizophrenia. Neuromolecular Med 9, 169177.
  • Shum, F.W., Ko, S.W., Lee, Y.S., Kaang, B.K. & Zhuo, M. (2005)Genetic alteration of anxiety and stress-like behavior in mice lacking CaMKIV. Mol Pain 15, 22.
  • Smith, S.M., Uslaner, J.M., Yao, L., Mullins, C.M., Surles, N.O., Huszar, S.L., McNaughton, C.H., Pascarella, D.M., Kandebo, M., Hinchliffe, R.M., Sparey, T., Brandon, N.J., Jones, B., Venkatraman, S., Young, M.B., Sachs, N., Jacobson, M.A. & Hutson, P.H. (2009) The behavioral and neurochemical effects of a novel D-amino acid oxidase inhibitor compound 8 [4H-thieno [3,2-b]pyrrole-5-carboxylic acid] and D-serine. J Pharmacol Exp Ther 328, 921930.
  • Soleimani, L., Roder, J.C., Dennis, J.W. & Lipina, T. (2008)Beta N-acetylglucosaminyltransferase V (Mgat5) deficiency reduces the depression-like phenotype in mice. Genes Brain Behav 7, 334343.
  • Swerdlow, N.R., Braff, D.L., Taaid, N. & Geyer, M.A. (1994) Assessing the validity of an animal model of deficient sensorimotor gaiting in schizophrenia patients. Arch Gen Psychiatry 51, 139154.
  • Tsai, G., Yang, P., Chung, L.-C., Lange, N. & Coyle, J.T. (1998)D-serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 44, 10811089.
  • Verrall, L., Walker, M., Rawlings, N., Benzel, I., Kew, J.N., Harrison, P.J. & Burnet, P.W. (2007) D-Amino acid oxidase and serine racemase in human brain: normal distribution and altered expression in schizophrenia. Eur J Neurosci 26, 16571669.
  • Wake, K., Yamazaki, H., Hanzawa, S., Konno, R., Sakio, H., Niwa, A. & Hori, Y. (2001) Exaggerated responses to chronic nociceptive stimuli and enhancement of N-methyl-D-aspartate receptor-mediated synaptic transmission in mutant mice lacking D-amino-acid oxidase. Neurosci Lett 297, 2528.
  • Weiner, I. (2003) The “two-headed” latent inhibition model of schizophrenia: modeling positive and negative symptoms and their treatment. Psychopharmacology 169, 257297.
  • Wersinger, S.R., Ginns, E.I., O’Carroll, A.M., Lolait, S.J. & Young W.S. III. (2002) Vasopressin V1b receptor knockout reduces aggressive behavior in male mice. Mol Psychiatry 7, 975984.
  • Wolosker, H., Sheth, K.N., Takahashi, M., Mothet, J.P., Brady, R.O. Jr, Ferris, C.D. & Snyder, S.H. (1999) Purification of serine racemase: Biosynthesis of the neuromodulator D-serine. Proc Natl Acad Sci U S A 96, 721725.
  • Wong, G.T. (2002) Speed congenics: applications for transgenic and knock-out mouse strains. Neuropeptides 36, 230236.
  • Wood, L.S., Pickering, E.H. & Dechairo, B.M. (2007) Significant support for DAO as a schizophrenia susceptibility locus: examination of five genes putatively associated with schizophrenia. Biol Psychiatry 61, 11951199.
  • Wu, S.Z., Bodles, A.M., Porter, M.M., Griffin, W.S., Basile, A.S. & Barger, S.W. (2004) Induction of serine racemase expression and D-serine release from microglia by amyloid beta-peptide. J Neuroinflammation 1, 2.
  • Yamada, K., Ohnishi, T., Hashimoto, K., Ohba, H., Iwayama-Shigeno, Y., Toyoshima. M., Okuno, A., Takao, H., Toyota, T., Minabe, Y., Nakamura, K., Shimizu, E., Itokawa, M., Mori, N., Iyo, M. & Yoshikawa, T. (2005) Identification of multiple serine racemase (SRR) mRNA isoforms and genetic analyses of SRR and DAO in schizophrenia and D-serine levels. Biol Psychiatry 57, 14931503.
  • Yang, Y., Ge, W., Chen, Y., Zhang, Z., Shen, W., Wu, C., Poo, M. & Duan, S. (2003) Contribution of astrocytes to hippocampal long-term potentiation through release of D-serine. Proc Natl Acad Sci U S A 100, 1519415199.